Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
← catalyst calendarNCT07007962 · readout in 443 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
36
Countries
Austria, Czechia, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | 2027-11-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immune Thrombocytopenia
Intervention
- Drug: rilzabrutinib — also filed as SAR444671
Primary outcome
what the primary-completion date above is the date OFDurable platelet response
measured Until Week 28
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed